within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M05B_DrugsAffectingBoneStructureAndMineralization.M05BA03_PamidronicAcid;
model PamidronicAcid 
   extends Pharmacolibrary.Drugs.ATC.M.M05BA03;

  annotation(Documentation(
    info ="<html><body><p>Pamidronic acid (pamidronate) is a bisphosphonate drug used primarily for the treatment of bone diseases such as Paget's disease, hypercalcemia of malignancy, and bone metastases associated with breast cancer and multiple myeloma. It is administered intravenously and is approved for clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult oncology patients (both sexes, age range 18-75) following intravenous administration.</p><h4>References</h4><ol><li><p>Dooley, M, &amp; Balfour, JA (1999). Ibandronate. <i>Drugs</i> 57(1) 101–110. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199957010-00011&quot;>10.2165/00003495-199957010-00011</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9951955/&quot;>https://pubmed.ncbi.nlm.nih.gov/9951955</a></p></li><li><p>Kellihan, MJ, &amp; Mangino, PD (1992). Pamidronate. <i>The Annals of pharmacotherapy</i> 26(10) 1262–1269. DOI:<a href=&quot;https://doi.org/10.1177/106002809202601015&quot;>10.1177/106002809202601015</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1421653/&quot;>https://pubmed.ncbi.nlm.nih.gov/1421653</a></p></li><li><p>Licata, AA (1997). Bisphosphonate therapy. <i>The American journal of the medical sciences</i> 313(1) 17–22. DOI:<a href=&quot;https://doi.org/10.1097/00000441-199701000-00004&quot;>10.1097/00000441-199701000-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9001162/&quot;>https://pubmed.ncbi.nlm.nih.gov/9001162</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end PamidronicAcid;
